drugset
drugset / Trial / NCT06085664

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

NCT06085664 ↗

Phase 1/2 Recruiting 42 enrolled M.D. Anderson Cancer Center
NaSequentialOpen-labelTreatment

Summary

To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.

Timeline

Start
2023-12-04
Primary completion
2028-06-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NEZASTOMIG Monoclonal antibody — Intravenous
Background 18F-DCFPyL Diagnostic / imaging agent — Intravenous

Indications

prostate cancer